Mange in Dogs: Sarcoptic vs Demodectic Types, Causes & Treatment

By Emiel Maddens  ·  Reviewed in consultation with licensed veterinary professionals  ·  Updated March 2026  ·  12 min read

Photo by Tima Miroshnichenko on Pexels

Mange is one of the most distressing conditions dog owners encounter. The intense itching, hair loss, and secondary skin infections that characterize this parasitic disease can quickly escalate to serious quality-of-life issues. Yet mange remains one of the most misunderstood dermatological conditions in veterinary medicine. Many owners and even some practitioners conflate the two primary forms—sarcoptic and demodectic mange—as though they were interchangeable conditions. In reality, they represent fundamentally different disease processes with distinct epidemiologies, clinical presentations, and treatment protocols.

This guide explores the biology of mites that cause mange, clarifies the clinical distinctions between sarcoptic and demodectic forms, and outlines evidence-based diagnostic and therapeutic approaches supported by peer-reviewed research. Understanding these differences is essential for rapid diagnosis, appropriate treatment selection, and reassuring worried owners about prognosis.

What Is Mange? Mite Biology Fundamentals

Mange is a parasitic skin condition caused by microscopic mites that colonize and reproduce within the canine epidermis and hair follicles. These arachnids—relatives of spiders and ticks—are permanent skin residents with complex life cycles adapted for survival in the warm, humid microenvironment of the skin surface and subsurface structures.

The Mite Life Cycle

Both sarcoptic and demodectic mites follow similar developmental patterns: eggs hatch into larvae, which progress through nymphal stages before reaching adulthood. The entire cycle—from egg to reproductive adult—typically spans 14–21 days, though environmental conditions and mite species influence duration. This rapid reproduction, particularly under favorable conditions, explains the exponential population growth that characterizes active mange infestations. A single pregnant female mite, if left untreated, can spawn thousands of descendants within weeks.

Understanding this reproductive timeline is critical for treatment planning. Most acaricides (mite-killing agents) target adult and nymphal stages effectively but may not penetrate deeply enough to destroy all eggs. This is why veterinarians often recommend repeated treatments at intervals timed to target newly emerged mites before they reach reproductive maturity.

Sarcoptic Mange: The Highly Contagious Form

Etiology and Epidemiology

Sarcoptes scabiei var. canis is an obligate parasite that cannot survive long off the host. These mites are highly host-adapted, meaning they have evolved to survive specifically on canine skin. They burrow through the stratum corneum (outer skin layer), creating tunnel-like galleries where females deposit eggs. This burrowing behavior triggers an intense inflammatory response and the characteristic severe itching associated with sarcoptic mange.

Transmission occurs through direct contact with infected animals or, less commonly, through contaminated fomites (bedding, grooming tools) within the first 24–48 hours of environmental exposure. Sarcoptic mange is zoonotic—it can infect humans, though typically causing mild, transient symptoms compared to the severe disease in dogs. Veterinary staff and owners often develop small, itchy pustules on their hands and forearms after handling infested dogs.

Clinical Presentation

Sarcoptic mange classically presents with an acute onset of severe pruritus (itching) that develops 2–4 weeks after exposure to infested animals. The condition typically begins on areas of thin skin: ear margins, elbows, hocks, and the ventral chest and abdomen. Initial lesions include erythema (redness), small papules (bumps), and excoriations (self-inflicted wounds from scratching).

If untreated, the condition progresses rapidly. Intense scratching leads to alopecia (hair loss), crusting, and lichenification (thickened, darkened skin). Secondary bacterial infections frequently develop, converting a primarily parasitic problem into a polymicrobial dermatitis. Some dogs develop generalized disease affecting the entire body, with affected animals experiencing sleep deprivation and profound discomfort. In severe cases, sarcoptic mange can contribute to weight loss, lethargy, and marked behavioral changes.

Demodectic Mange: The Immune-Related Form

Biology and Pathophysiology

Demodex canis mites are commensal organisms—permanent, normal residents of canine skin. Puppies acquire these mites through nursing and maternal contact in the first few days of life. In immunocompetent dogs, Demodex populations remain controlled and cause no disease. However, when cellular immunity is compromised—whether through age, genetics, stress, malnutrition, systemic disease, or medication—mite populations explode unchecked, triggering inflammation and the clinical signs of demodicosis (demodectic mange).

This fundamental difference makes demodectic mange non-contagious. A healthy dog cannot "catch" demodicosis from an infected companion because the mites are ubiquitous on normal skin. Disease emerges only when the host's immune system fails to maintain population control.

Clinical Forms and Presentation

Demodectic mange presents in two distinct forms: localized and generalized. Localized demodicosis affects small, circumscribed body regions (typically the face, eyelids, or forelimbs) and is characterized by patchy alopecia, mild erythema, and scaling. Pruritus is absent or minimal. This form commonly affects young dogs (3–12 months) and often resolves spontaneously as immune competence develops with maturation. The prognosis for localized disease is excellent, with up to 90% of cases self-resolving.

Generalized demodicosis involves multiple body regions and often affects older dogs or those with underlying systemic disease (hypothyroidism, diabetes, malignancy, immunosuppression). Affected dogs present with extensive alopecia, erythema, scaling, and often develop secondary pyoderma (bacterial skin infection), which complicates diagnosis and treatment. Pruritus may develop secondarily as a result of bacterial infection rather than the mites alone.

Diagnostic Methods: Identifying the Type of Mange

Skin Scrapings

Deep skin scrapings remain the gold-standard diagnostic technique for mange identification. The procedure involves scraping affected skin with a blunt scalpel blade to collect samples from the epidermis and superficial dermis. Scrapings should be vigorous enough to cause mild bleeding, ensuring adequate collection of subsurface mites. The harvested material is then mixed with mineral oil and examined under microscopic magnification for mite identification.

For sarcoptic mange, multiple scraping sites increase diagnostic yield, as mite density is variable and scattered across the body. For demodectic mange, scrapings from the junction between affected and normal skin often yield the highest mite counts. A negative scraping does not rule out sarcoptic mange; up to 50% of infected dogs may have non-diagnostic scrapings despite active infection. In these cases, trial therapeutic protocols or alternative diagnostic methods become necessary.

Tape-Strip Tests and Dermatoscopy

Scotch tape-strip tests provide a less invasive alternative to scrapings, particularly useful for facial lesions or in anxious animals. Clear adhesive tape is pressed against affected skin and then examined microscopically. While sensitive for demodectic mites, tape tests may miss sarcoptic mites in deeper burrows. Dermatoscopy—non-invasive visualization using magnification and polarized light—is increasingly available in veterinary dermatology clinics and can visualize mites and burrows without tissue trauma.

When diagnostic uncertainty persists, empiric treatment for sarcoptic mange is often justified given its zoonotic potential and severe clinical progression. Veterinarians may initiate treatment while continuing diagnostic efforts with repeated scrapings or pursuing emerging tests such as PCR-based mite detection.

Evidence-Based Treatment Protocols

Sarcoptic Mange Treatment

Sarcoptic mange responds excellently to acaricidal therapy. First-line options include:

• Ivermectin (oral): Administered weekly for 4–6 weeks at 0.2–0.4 mg/kg. Highly effective and cost-efficient. Contraindicated in ivermectin-sensitive breeds (some herding dogs with MDR1 mutations).
• Selamectin (topical): Applied monthly for 3–4 months. Excellent safety profile, suitable for young and senior dogs. Often preferred in first-line protocols.
• Moxidectin (injectable): Administered as two injections 2 weeks apart. Long-acting acaricide with high efficacy, particularly in difficult-to-treat or refractory cases.
• Lime sulfur dips: Applied weekly for 4–6 weeks. Older protocol with lower toxicity profile but unpleasant odor and staining; now reserved for cases where other agents cannot be used.

Concurrent supportive care accelerates clinical improvement. Anti-inflammatory therapy (prednisolone or methylprednisolone at immunosuppressive doses for 2–4 weeks) reduces pruritus and secondary trauma. Topical antimicrobial treatments address secondary bacterial infections and provide comfort. Products like Vetified Itchy Skin Relief Spray provide soothing relief while treatment takes effect, though they should not be viewed as replacements for specific acaricide therapy.

Environmental sanitation is important but not sufficient as a sole intervention. Infested bedding should be discarded or thoroughly laundered in hot water; grooming tools should be disinfected or replaced. However, the parasite's dependence on living host tissue makes environmental control a secondary consideration compared to systemic acaricide administration.

Demodectic Mange Treatment

Localized demodicosis often requires no treatment beyond monitoring. Observation over 8–12 weeks is reasonable, as spontaneous resolution occurs in the majority of young dogs. If lesions progress or owner concern warrants intervention, topical acaricides (amitraz or sulfurated lime) applied weekly for 4–6 weeks, combined with benzoyl peroxide shampoos, are effective and minimize systemic effects.

Generalized demodicosis requires systemic therapy. Oral ivermectin (0.1–0.2 mg/kg daily) or milbemycin oxime (2 mg/kg daily) administered for 6–12 weeks represents standard practice. Treatment duration depends on clinical response, as determined by repeat skin scrapings showing mite reduction. Many cases require extended therapy (12+ weeks) with gradual tapering to prevent relapse.

Critically, identifying and treating the underlying cause of immune dysfunction is essential for success. Screening should include thyroid function tests (T4, free T4, TSH) in older dogs, fasting blood glucose assessment, and evaluation for occult malignancy or inflammatory conditions. Nutritional optimization—ensuring adequate protein, essential fatty acids, and micronutrient intake—supports immune reconstitution.

In both forms, supportive topical therapy promotes healing and comfort. Regular bathing with medicated shampoos containing benzoyl peroxide, coal tar, or sulfur provides additional anti-parasitic and anti-inflammatory benefits. Antibiotic therapy is indicated when secondary pyoderma develops, guided by culture and sensitivity when possible.

Prognosis and Long-Term Outcomes

The prognosis for mange varies substantially based on type, severity, and comorbidities. Sarcoptic mange has an excellent prognosis when appropriately treated. The majority of dogs achieve clinical cure within 4–6 weeks, with complete resolution of lesions and normalization of skin health by 8–12 weeks. Recurrence is rare in immunocompetent dogs with exposure to adequate acaricide therapy, as the parasite cannot establish persistent infection once eliminated.

Localized demodicosis similarly carries an excellent prognosis, with spontaneous resolution in 80–90% of young dogs and cure rates exceeding 95% with treatment. Generalized demodicosis is more guarded, with cure rates ranging from 40% to 85% depending on the underlying cause and success of immunological restoration. Dogs with generalized disease secondary to malignancy or severe immunosuppression may not achieve full remission, though disease management can improve comfort and quality of life.

For all forms of mange, monitoring for relapse is prudent. Dogs with demodectic disease should be monitored periodically with repeat scrapings and clinical assessment, particularly if they required extended acaricide therapy or if underlying immune dysfunction persists. Post-treatment supportive care—including optimized nutrition, stress reduction, and ongoing management of any systemic disease—helps maintain immune competence and prevent recurrence.

Frequently Asked Questions

References

1. Noli, C., Toma, S. (2006). "Sarcoptic Mange in Dogs and Cats: Biology, Epidemiology, Clinical Features, Diagnosis and Treatment." Veterinary Dermatology, 17(5), 313–323.
2. Mueller, R. S., Bensignor, E., Ferrer, L., et al. (2012). "Treatment of Demodicosis in Dogs: 2011 Clinical Consensus Guidelines of the International Society of Feline Medicine." Veterinary Dermatology, 23(2), 86–96.
3. Saridomichelakis, M. N. (2007). "Advances in Diagnostic and Therapeutic Approaches to Canine Demodicosis." Journal of Small Animal Practice, 48(6), 308–316.
4. Schuster, R. K. (2006). "Demodex mites: Ectoparasites of Dermatological Importance." Journal of the American Animal Hospital Association, 40(3), 179–189.
5. Bensignor, E., Carlotti, D. N. (2003). "Efficacy of Injected Ivermectin in the Treatment of Canine Scabies." Veterinary Dermatology, 14(3), 134–138.
6. Paradis, M. (2009). "Update on the Management of Canine Demodicosis." Clinical Techniques in Small Animal Practice, 21(4), 186–191.
7. Ghubash, R. (2006). "Allergic Skin Disease of Dogs and Cats: A Guide to Diagnosis and Treatment." Veterinary Medicine, 101(7), 46–61.

Emiel Maddens

Founder of Vetified. Develops topical antifungal and antimicrobial formulations for companion animals. Vetified products are listed on DailyMed and manufactured through FDA-registered facilities in the United States.

Veterinary review: All Vetified content is developed in consultation with licensed veterinary professionals and references peer-reviewed research published in journals including Veterinary Dermatology, JAVMA, and Journal of Small Animal Practice.